三部门:将含羟考酮复方制剂等品种列入精神药品管理

2019-08-07 余静英 央视新闻客户端

国家药监局、公安部、国家卫生健康委发布将含羟考酮复方制剂等品种列入精神药品管理的公告。根据《麻醉药品和精神药品管理条例》有关规定,国家药品监督管理局、公安部、国家卫生健康委员会决定,将含羟考酮复方制剂等品种列入精神药品管理。现公告如下:一、口服固体制剂每剂量单位含羟考酮碱大于5毫克,且不含其它麻醉药品、精神药品或药品类易制毒化学品的复方制剂列入第一类精神药品管理;二、口服固体制剂每剂量单位含羟考酮

国家药监局、公安部、国家卫生健康委发布将含羟考酮复方制剂等品种列入精神药品管理的公告。

根据《麻醉药品和精神药品管理条例》有关规定,国家药品监督管理局、公安部、国家卫生健康委员会决定,将含羟考酮复方制剂等品种列入精神药品管理。现公告如下:

一、口服固体制剂每剂量单位含羟考酮碱大于5毫克,且不含其它麻醉药品、精神药品或药品类易制毒化学品的复方制剂列入第一类精神药品管理;

二、口服固体制剂每剂量单位含羟考酮碱不超过5毫克,且不含其它麻醉药品、精神药品或药品类易制毒化学品的复方制剂列入第二精神药品管理;

三、丁丙诺啡与纳洛酮的复方口服固体制剂列入第二类精神药品管理。

本公告自2019年9月1日起施行。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1659391, encodeId=aa371659391e0, content=<a href='/topic/show?id=7f998e468c2' target=_blank style='color:#2F92EE;'>#药品管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87468, encryptionId=7f998e468c2, topicName=药品管理)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=232724968866, createdName=pcw114, createdTime=Tue Dec 03 10:52:00 CST 2019, time=2019-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2019799, encodeId=05942019e994c, content=<a href='/topic/show?id=5db7e6576d0' target=_blank style='color:#2F92EE;'>#精神药品#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76576, encryptionId=5db7e6576d0, topicName=精神药品)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI5PdY90y5Jib8FnPhCXTR2d9v3K17epNSwB2eb0vmXUldNJl2e72S4unZTAHLAojicdVSialTDFHAxA/132, createdBy=78d82500042, createdName=ms7514935887898259, createdTime=Tue Oct 08 16:52:00 CST 2019, time=2019-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1948439, encodeId=196b1948439b8, content=<a href='/topic/show?id=44a48001672' target=_blank style='color:#2F92EE;'>#羟考酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80016, encryptionId=44a48001672, topicName=羟考酮)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/D2FD7704B41C9E22364B1E54ABB223BB/100, createdBy=1df22500220, createdName=ms1260584454294838, createdTime=Mon Apr 27 23:52:00 CST 2020, time=2020-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601056, encodeId=e1ce160105688, content=<a href='/topic/show?id=dd43426460c' target=_blank style='color:#2F92EE;'>#复方制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42646, encryptionId=dd43426460c, topicName=复方制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=279318829047, createdName=chengjn, createdTime=Thu Aug 08 16:52:00 CST 2019, time=2019-08-08, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1659391, encodeId=aa371659391e0, content=<a href='/topic/show?id=7f998e468c2' target=_blank style='color:#2F92EE;'>#药品管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87468, encryptionId=7f998e468c2, topicName=药品管理)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=232724968866, createdName=pcw114, createdTime=Tue Dec 03 10:52:00 CST 2019, time=2019-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2019799, encodeId=05942019e994c, content=<a href='/topic/show?id=5db7e6576d0' target=_blank style='color:#2F92EE;'>#精神药品#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76576, encryptionId=5db7e6576d0, topicName=精神药品)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI5PdY90y5Jib8FnPhCXTR2d9v3K17epNSwB2eb0vmXUldNJl2e72S4unZTAHLAojicdVSialTDFHAxA/132, createdBy=78d82500042, createdName=ms7514935887898259, createdTime=Tue Oct 08 16:52:00 CST 2019, time=2019-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1948439, encodeId=196b1948439b8, content=<a href='/topic/show?id=44a48001672' target=_blank style='color:#2F92EE;'>#羟考酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80016, encryptionId=44a48001672, topicName=羟考酮)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/D2FD7704B41C9E22364B1E54ABB223BB/100, createdBy=1df22500220, createdName=ms1260584454294838, createdTime=Mon Apr 27 23:52:00 CST 2020, time=2020-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601056, encodeId=e1ce160105688, content=<a href='/topic/show?id=dd43426460c' target=_blank style='color:#2F92EE;'>#复方制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42646, encryptionId=dd43426460c, topicName=复方制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=279318829047, createdName=chengjn, createdTime=Thu Aug 08 16:52:00 CST 2019, time=2019-08-08, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1659391, encodeId=aa371659391e0, content=<a href='/topic/show?id=7f998e468c2' target=_blank style='color:#2F92EE;'>#药品管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87468, encryptionId=7f998e468c2, topicName=药品管理)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=232724968866, createdName=pcw114, createdTime=Tue Dec 03 10:52:00 CST 2019, time=2019-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2019799, encodeId=05942019e994c, content=<a href='/topic/show?id=5db7e6576d0' target=_blank style='color:#2F92EE;'>#精神药品#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76576, encryptionId=5db7e6576d0, topicName=精神药品)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI5PdY90y5Jib8FnPhCXTR2d9v3K17epNSwB2eb0vmXUldNJl2e72S4unZTAHLAojicdVSialTDFHAxA/132, createdBy=78d82500042, createdName=ms7514935887898259, createdTime=Tue Oct 08 16:52:00 CST 2019, time=2019-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1948439, encodeId=196b1948439b8, content=<a href='/topic/show?id=44a48001672' target=_blank style='color:#2F92EE;'>#羟考酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80016, encryptionId=44a48001672, topicName=羟考酮)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/D2FD7704B41C9E22364B1E54ABB223BB/100, createdBy=1df22500220, createdName=ms1260584454294838, createdTime=Mon Apr 27 23:52:00 CST 2020, time=2020-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601056, encodeId=e1ce160105688, content=<a href='/topic/show?id=dd43426460c' target=_blank style='color:#2F92EE;'>#复方制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42646, encryptionId=dd43426460c, topicName=复方制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=279318829047, createdName=chengjn, createdTime=Thu Aug 08 16:52:00 CST 2019, time=2019-08-08, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1659391, encodeId=aa371659391e0, content=<a href='/topic/show?id=7f998e468c2' target=_blank style='color:#2F92EE;'>#药品管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87468, encryptionId=7f998e468c2, topicName=药品管理)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=232724968866, createdName=pcw114, createdTime=Tue Dec 03 10:52:00 CST 2019, time=2019-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2019799, encodeId=05942019e994c, content=<a href='/topic/show?id=5db7e6576d0' target=_blank style='color:#2F92EE;'>#精神药品#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76576, encryptionId=5db7e6576d0, topicName=精神药品)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI5PdY90y5Jib8FnPhCXTR2d9v3K17epNSwB2eb0vmXUldNJl2e72S4unZTAHLAojicdVSialTDFHAxA/132, createdBy=78d82500042, createdName=ms7514935887898259, createdTime=Tue Oct 08 16:52:00 CST 2019, time=2019-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1948439, encodeId=196b1948439b8, content=<a href='/topic/show?id=44a48001672' target=_blank style='color:#2F92EE;'>#羟考酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80016, encryptionId=44a48001672, topicName=羟考酮)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/D2FD7704B41C9E22364B1E54ABB223BB/100, createdBy=1df22500220, createdName=ms1260584454294838, createdTime=Mon Apr 27 23:52:00 CST 2020, time=2020-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601056, encodeId=e1ce160105688, content=<a href='/topic/show?id=dd43426460c' target=_blank style='color:#2F92EE;'>#复方制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42646, encryptionId=dd43426460c, topicName=复方制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=279318829047, createdName=chengjn, createdTime=Thu Aug 08 16:52:00 CST 2019, time=2019-08-08, status=1, ipAttribution=)]